Cambium Bio Limited (ASX: CMB) - Share Price
Current share price for CMB : $0.460 0.01 (2.22%)+
Cambium Bio Limited (CMB), an ASX-listed company, is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications.
CMB General Information +
| ASX Code | CMB |
| Website | http://www.cambium.bio |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 12 |
| CMB Share Price | $0.460 |
| Day High | $0.460 |
| Day Low | $0.460 |
| Last Close | $0.450 |
| CMB Share Price Movement | $0.01 ( 2.22% ) |
Prices as at 16:35, 23 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Cambium Bio Limited (CMB) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Cambium Bio Limited (CMB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Cambium Bio Limited (CMB) price-sensitive announcements
CMB - Quarterly Activities/Appendix 4C Cash Flow Report
The quarterly report for Cambium Bio Limited details significant advancements in their cli
Cambium Bio Limited (CMB)
28 Apr 2026 | 9:10 AM
28 Apr 2026 | 9:10 AM
CMB - FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
Cambium Bio Limited announced that the FDA has confirmed a single pivotal trial pathway fo
Cambium Bio Limited (CMB)
23 Apr 2026 | 1:01 PM
23 Apr 2026 | 1:01 PM
CMB - Half Year Report and Accounts
During the half-year ended 31 December 2025, Cambium Bio Limited made significant progress
Cambium Bio Limited (CMB)
20 Feb 2026 | 9:39 AM
20 Feb 2026 | 9:39 AM
CMB - Quarterly Activities/Appendix 4C Cash Flow Report
Cambium Bio Limited, a clinical-stage regenerative medicine company, released a quarterly
Cambium Bio Limited (CMB)
23 Jan 2026 | 9:14 AM
23 Jan 2026 | 9:14 AM
Cambium Bio Limited (CMB) Recent ASX Announcements
CMB Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$3.84 | -$21.00 | -55.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.96 | -$47.10 | 4,257.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$3.30 | -$1.10 | -22.30% | 0.00 | 0.00 | 0.00% | 0.0% |
CMB Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Cambium Bio Limited (CMB) | $13M | -0.5531 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| CSL Limited (CSL) | $55,707M | 0.1108 | -0.1327 | 0.0165 | 12.4731 | 14.3820 | 14.1481 | 3.83% | 3.09% | 3.21% |
| Clinuvel Pharmaceuticals Limited (CUV) | $519M | 0.0287 | 0.0233 | 0.0942 | 14.3454 | 14.0193 | 12.8125 | 0.49% | 0.70% | 1.14% |
| Mesoblast Limited (MSB) | $2,758M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,921M | -1.3893 | 0.0000 | -0.1308 | 0.0000 | 271.0280 | 311.8280 | 0.00% | 0.00% | 0.00% |
CMB Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 4.48 | 0.00 |
| Market | 0.29 | 13.20 | 1.17 | 0.67 |
| Sector | 0.43 | 26.20 | 2.49 | 2.38 |
CMB Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Edmund Waller | Chief Scientific Officer, Executive Director, Executive Chairman | 5 Apr 2024 |
| Mr Terence A Walts | Executive Director | 5 Apr 2024 |
| Dr Yu-Hung Sebastian Tseng | Non-Executive Director | 11 Apr 2024 |
| Dr ChiTai Chang | Non-Executive Director | 10 Oct 2024 |
| Professor Chandra Bala | Non-Executive Director | 22 Nov 2024 |
| Mr Li Chien Chiu | Non-Executive Director | 7 Mar 2025 |
| Dr Denese Marks | Non-Executive Director | 21 May 2025 |
Cambium Bio Limited (CMB) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 17 Mar 2026 | TSENG, Yu-Hung | Issued | Indirect Shares | 4,363,637 | $0.550 | $2,400,000.350 |
| 16 Oct 2025 | WALLER, Edmund | Issued | Direct Shares | 60,000 | $0.464 | $27,822.000 |
| 16 Oct 2025 | WALTS, Terence | Issued | Direct Shares | 54,950 | $0.464 | $25,480.315 |
See all changes in directors' interest & trades for Cambium Bio Limited (CMB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CMB Management
| Name | Position |
|---|---|
| Mark Andrew Licciardo | Company Secretary |
CMB Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in -- (CMB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 2,688,506 (14.56%) | Zheng Yang Biomedical Technology Co Ltd |
| 2,384,359 (12.91%) | Cyntec Co Ltd |
| 999,002 (5.41%) | Treasure Century Group Limited |
| 800,357 (4.33%) | Li-Chien Ken Chiu |
| 691,580 (3.74%) | Apex Metro Investments Limited |
CMB Calendar of Events
| Date | Event |
|---|---|
| 19 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
